{"filings":[{"id":1397476,"accession_number":"0001193125-26-293485","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2026-07-02T12:00:40+00:00","items":["8.01","9.01"],"status":"ready","headline":"Tenax Therapeutics to present Phase 3 LEVEL trial results at ESC Congress 2026; topline data expected in August","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 LEVEL trial results to be presented in Late-Breaking Clinical Science session at ESC Congress 2026 (Aug 28-31, Munich).","Company expects to report topline data in August 2026; database lock and statistical analysis underway.","Trial evaluates TNX-103 (oral levosimendan) in PH-HFpEF; enrollment of >230 patients completed March 2026.","BSSR in Dec 2025 showed >90% power to detect 25m change in 6MWD primary endpoint."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1361403,"accession_number":"0001193125-26-290661","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2026-06-30T20:30:25+00:00","items":["1.01","9.01"],"status":"ready","headline":"Tenax Therapeutics enters supply agreement with Orion; extends regulatory approval deadline to 2035","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Supply Agreement with Orion for oral levosimendan; 5-year initial term, auto-renewing 3-year periods.","Sixth Amendment extends U.S. regulatory approval deadline to December 31, 2035; failure allows termination.","Company must comply with Orion's General Information and Cybersecurity Requirements as part of amendment.","Supply Agreement includes cost-sharing provisions for scaling Orion's manufacturing capabilities.","Either party may terminate for material breach (60-day cure) or insolvency; also tied to License Agreement termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1334517,"accession_number":"0001193125-26-288600","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2026-06-29T20:40:44+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Tenax adopts CIC/Severance Plans; amends CEO Giordano's agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board adopted double-trigger Change in Control Plan and Severance Plan on June 26, 2026.","CEO Giordano: 18 months' base salary + target bonus + accelerated vesting on CIC termination.","Executives Staab and Rich: 12 months' base salary + COBRA on CIC; non-CIC severance includes 12-month base plus extra base per year of service up to 12 additional months.","Benefits under plans and amendments conditioned on execution of release of claims.","Executive officers excluded from new plans; covered via individual amended agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":861079,"accession_number":"0001193125-26-257400","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2026-06-04T20:10:06+00:00","items":["5.07"],"status":"ready","headline":"Tenax Therapeutics reports results of 2026 annual shareholder meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected seven directors: June Almenoff (17.36M for), Michael Davidson (15.76M), Declan Doogan, Christopher T. Giordano, Robyn M. Hunter, Gerald T. Proehl, Stuart Rich.","Auditor Cherry Bekaert LLP ratified with 21.30M for, 3,688 against, 11,073 abstain, no broker non-votes.","All director nominees received over 17.3 million votes in favor except Michael Davidson with 15.76 million.","The meeting was held on June 2, 2026; results filed June 4, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22730,"accession_number":"0001193125-26-218224","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2026-05-12T12:00:07+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenax Q1 net loss $15.7M; cash $118.8M; Phase 3 topline data expected Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.7M for Q1 2026 vs $10.4M in Q1 2025; R&D expense rose to $11.5M from $5.7M.","Cash and equivalents $118.8M as of March 31, 2026; expected to fund operations through at least Q1 2028.","Phase 3 LEVEL study fully randomized (>230 patients); topline data anticipated in Q3 2026.","Appointed Thomas Staab as CFO, Timothy Healey as CCO, and So-Young Kim as EVP Clinical Development.","Phase 3 LEVEL-2 trial ongoing; enrollment completion expected by end of 2027."],"consensus_eps_estimate":-0.408,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98015,"accession_number":"0001193125-26-168521","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Tenax Therapeutics appoints Thomas R. Staab, II as CFO effective May 11, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Staab, a 25-year healthcare finance veteran, most recently CFO of LENSAR (LNSR) until May 2026.","Base salary of $428,000 with 45% target bonus; inducement equity of 10,000 RSUs and 450,000 option shares.","Interim CFO Thomas McGauley resigns May 10, 2026 but will stay through filing of Q1 10-Q and provide consulting transition.","Staab's RSUs vest 25% after 10 days, remainder quarterly; options vest 25% after 1 year then monthly over 3 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113244,"accession_number":"0001654954-26-002072","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenax Therapeutics reports Q4/FY2025 loss; LEVEL study fully enrolled, topline Q3 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Achieved 230-patient randomization target in Phase 3 LEVEL study; topline data expected Q3 2026.","Cash and equivalents $97.6M as of Dec 31, 2025; expected to fund operations through 2027.","Full-year 2025 net loss $52.6M vs $17.6M in 2024; R&D spend $32.7M on trial expansion.","Initiated global Phase 3 LEVEL-2 trial and open-label extension for TNX-103 (levosimendan) in PH-HFpEF.","USPTO issued Notice of Allowance for subcutaneous levosimendan formulation in broad indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113243,"accession_number":"0001654954-26-000232","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Tenax CMO Dr. Stuart Rich moves to 4-day work week; salary prorated 80%","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective Jan 1, 2026, Dr. Rich will average 4 days per week as CMO.","Annual base salary prorated to 80% (80% of prior salary) reflecting reduced schedule.","Board approved amendment on Dec 22, 2025; executed Jan 6, 2026.","Executive acknowledges voluntary consent and no 'Good Reason' for termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129630,"accession_number":"0001654954-25-014059","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Tenax Therapeutics confirms LEVEL Phase 3 trial enrollment on track; initiates global LEVEL-2 study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Blinded Sample Size Re-estimation (BSSR) shows LEVEL is powered >90% to detect 25m change in 6MWD primary endpoint.","LEVEL enrollment completion reaffirmed for H1 2026; topline data expected in H2 2026.","Global Phase 3 LEVEL-2 study initiated targeting ~540 PH-HFpEF patients; enrollment completion estimated by end of 2027.","Company plans to launch a long-term open-label extension (OLE) study for continued access to TNX-103.","Results confirm standard deviation lower than assumed 55 meters, de-risking trial design."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129629,"accession_number":"0001654954-25-012921","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenax Therapeutics Q3 net loss $15.8M; Phase 3 LEVEL enrollment on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.8M for Q3 2025 vs $4.0M in Q3 2024; R&D expenses $10.3M (up from $3.1M).","Cash and cash equivalents $99.4M as of Sept 30, 2025; expected to fund operations through 2027.","Phase 3 LEVEL study (TNX-103) targeting 230 patients; enrollment completion expected H1 2026, topline data H2 2026.","On track to initiate second Phase 3 study LEVEL-2 in 2025; 160+ global sites qualified.","European Patent Office intends to grant patent for levosimendan in PH-HFpEF, extending IP to Dec 2040."],"consensus_eps_estimate":-0.3188,"consensus_eps_actual":-0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146211,"accession_number":"0001654954-25-010792","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Tenax Therapeutics receives EPO intention to grant patent for levosimendan in PH-HFpEF through 2040","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["EPO intends to grant patent covering TNX-103 (oral levosimendan) and other formulations for PH-HFpEF.","European patent protection through at least December 2040, with potential SPC extension beyond.","Patent also covers active metabolites OR1896/OR1855 and combination with other cardiovascular drugs.","Builds on existing U.S. and Canada patents; supports Phase 3 LEVEL-2 study initiation expected this year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146210,"accession_number":"0001654954-25-010510","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Tenax Therapeutics expands levosimendan license to exclusive worldwide oral rights; gains manufacturing rights","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment with Orion grants Tenax exclusive worldwide rights to develop, commercialize, and manufacture oral levosimendan products.","Tenax also obtains manufacturing rights for subcutaneously administered levosimendan products under the expanded license.","Orion will supply levosimendan API at low triple-digit thousand Euros/kg, minimum order [***] grams, payment within 45 days.","Fifth Amendment builds on prior agreements; effective September 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146209,"accession_number":"0001654954-25-009510","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenax Therapeutics reports Q2 net loss of $10.9M; Phase 3 LEVEL study enrollment on track for H1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.9M in Q2 2025 vs $3.6M in Q2 2024; R&D spend $6.1M, G&A $5.7M.","Cash and equivalents of $105.5M as of June 30, 2025, expected to fund operations through 2027.","Phase 3 LEVEL study (TNX-103) enrollment target of 230 patients; completion expected H1 2026, topline data H2 2026.","On track to initiate second Phase 3 study, LEVEL-2, in 2025 with over 85 sites in 15 countries qualified.","Canadian patent allowed for TNX-103/102/101 and metabolites in PH-HFpEF, extending protection to 2040."],"consensus_eps_estimate":-0.2448,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164543,"accession_number":"0001654954-25-007104","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Tenax Therapeutics shareholders approve officer exculpation, reject meeting-vote mandate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved officer exculpation amendment (2,458,203 for, 10,244 against); effective upon filing.","All seven director nominees elected; June Almenoff received 2,460,500 votes in favor.","Proposal requiring all stockholder action at meetings rejected (1,915,960 for, 563,768 against).","Non-binding say-on-pay approved (2,435,043 for); advisory vote to occur every two years.","Cherry Bekaert LLP ratified as auditor for FY2025 (2,976,524 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164542,"accession_number":"0000950170-25-071382","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenax Therapeutics Q1 net loss $10.4M; Phase 3 LEVEL enrollment on track for year-end 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $10.4M in Q1 2025 vs $3.8M in Q1 2024; company is a development-stage biotech with no revenue.","Cash and equivalents $111.4M as of March 31, 2025; raised ~$25M gross proceeds from private placement in March 2025.","Phase 3 LEVEL study enrollment of 230 patients in PH-HFpEF targeted for completion around year-end 2025; topline data mid-2026.","Initiation of second registrational Phase 3 study (LEVEL-2) for TNX-103 expected in 2025.","R&D expense $5.7M (up from $2.7M) and G&A $5.7M (up from $1.2M) due to trial costs and stock-based compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182298,"accession_number":"0000950170-25-044375","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenax Therapeutics reports FY2024 net loss of $17.6M; $94.9M cash; raised $125M for TNX-103 Phase 3 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2024 was $17.6M vs $7.7M in 2023; Q4 net loss $6.3M vs $3.2M.","Cash and cash equivalents $94.9M as of Dec 31, 2024; plus $25M March 2025 private placement, funding through 2027.","Phase 3 LEVEL study enrollment expanded to 230 patients; topline data expected mid-2026.","Second Phase 3 study LEVEL-2 expected to initiate in 2025.","R&D expenses $12.7M in 2024 vs $3.2M in 2023, driven by Phase 3 LEVEL study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182297,"accession_number":"0001654954-25-002385","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Tenax raises $25M, expands Phase 3 LEVEL study to 230 patients, adds LEVEL-2 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement with RTW Investments grossed ~$25M; issued 378K shares + pre-funded warrants for 3.76M shares at $6.04/$6.03.","FDA accepted amendment to expand LEVEL study from 152 to 230 patients, increasing statistical power to >95%; enrollment expected by end of 2025.","FDA agreed to initiate second global Phase 3 LEVEL-2 study; first patient expected in 2025; primary endpoint 6MWD at 26 weeks.","Blinded LEVEL data shows >95% patients remain on therapy, no safety signals; topline data expected mid-2026.","Proceeds extend cash runway through end of 2027, funding Phase 3 trials and operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198915,"accession_number":"0001654954-24-015161","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2024-12-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Tenax Therapeutics appoints Thomas A. McGauley as Interim CFO, effective Dec 2, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas A. McGauley appointed Interim CFO and principal financial/accounting officer, replacing Lawrence R. Hoffman.","McGauley provides services through Danforth Advisors at $410 per hour with up to 4% annual increase.","McGauley has 25+ years financial experience, including interim CFO at Galectin Therapeutics and manager at PwC.","He holds a CPA and B.S.B.A in Accounting from Stonehill College; no familial relationships with officers or directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198914,"accession_number":"0001654954-24-014203","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenax Therapeutics Q3 net loss $4.0M; raised $100M private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.0M for Q3 2024 vs $2.0M in Q3 2023; R&D expenses $3.1M (up from $1.1M).","Cash, cash equivalents and investments $98.3M as of Sept 30, 2024, vs $9.8M at Dec 31, 2023.","Closed private placement in Aug 2024 yielding approximately $100M gross proceeds.","Phase 3 LEVEL study for levosimendan ongoing: 52 investigative sites initiated, enrolling patients.","Cash runway projected through end of 2027 based on current operating plan."],"consensus_eps_estimate":-0.3188,"consensus_eps_actual":-1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198913,"accession_number":"0001654954-24-013505","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve 7.9M share increase in 2022 Stock Incentive Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved Amendment No. 2 to 2022 Stock Incentive Plan, increasing authorized shares to 8,336,600 (7,935,912 new shares).","Vote: 1,176,335 for, 157,003 against, 3,849 abstentions; no broker non-votes.","Board approved amendment on Sept 6, 2024; stockholders approved on Oct 25, 2024.","Adjournment proposal also approved: 1,194,879 for, 139,002 against, 3,306 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214950,"accession_number":"0001654954-24-010454","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenax Therapeutics reports Q2 net loss of $3.6M, cash $9.4M; raised $100M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.6M ($1.83/sh) vs loss of $1.1M ($4.00/sh) in Q2 2023.","R&D expenses $2.3M, up from $0.2M due to Phase 3 LEVEL study costs.","Cash and equivalents $9.4M at June 30; subsequent private placement raised $100M gross.","Phase 3 LEVEL study enrolling with 39 investigative sites; patent granted for levosimendan in PH-HFpEF.","G&A expenses $1.3M vs $1.0M in prior-year quarter."],"consensus_eps_estimate":-0.2448,"consensus_eps_actual":-4.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214949,"accession_number":"0001654954-24-010278","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Tenax Therapeutics closes $100M private placement to fund Phase 3 levosimendan program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$100M from oversubscribed private placement led by BVF Partners.","Issued 1,450,661 common shares at $3.00, plus pre-funded warrants for 31,882,671 shares and warrants for 16,666,666 shares.","Funds will complete ongoing LEVEL Phase 3 study and initiate a second Phase 3 study in 2025, shortening NDA timeline.","Oral levosimendan (TNX-103) targets PH-HFpEF, a disease with no approved therapies; earlier HELP study showed 29-meter 6MWD improvement.","Leerink Partners, Guggenheim Securities, and William Blair acted as placement agents; ROTH Capital advised Tenax."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214948,"accession_number":"0001654954-24-009988","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Tenax Therapeutics Raises $100M in Oversubscribed Private Placement Led by BVF Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$100M from 1.45M shares, 31.9M pre-funded warrants, and 16.7M warrants at $3.00/share (warrant strike $4.50).","Private placement led by BVF Partners LP; new investors include Venrock, Vivo Capital, Janus Henderson, Vestal Point, Velan Capital, ADAR1, Stonepine, Sphera Biotech.","Net proceeds to complete Phase 3 LEVEL trial and initiate second Phase 3 trial of oral levosimendan; cash runway extended through end of 2027.","Expected to close August 8, 2024; Leerink Partners lead placement agent, with Guggenheim, William Blair as joint agents; ROTH Capital financial advisor.","Post-closing common shares outstanding expected to be approximately 3.4 million."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234153,"accession_number":"0001654954-24-007727","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Tenax Therapeutics expands equity pool by 400k shares; CMO shifts to part-time","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stockholders approved Amendment No. 1 to 2022 Stock Incentive Plan, increasing authorized shares to 400,688.","CMO Dr. Stuart Rich will work 3 days/week from June 15, 2024; annual base salary of $333,900 prorated to 60%.","Board elected; auditor Cherry Bekaert LLP ratified. Next advisory vote on exec compensation set for 2025 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234152,"accession_number":"0001654954-24-006131","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenax Therapeutics Q1 net loss widens to $3.8M; Phase 3 LEVEL study enrolling","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.8M vs $1.4M in Q1 2023; R&D expenses rose to $2.7M from $0.3M.","Cash $12.5M; raised ~$8.0M net in Feb 2024 public offering.","Phase 3 LEVEL study for PH-HFpEF enrolling; 24 sites initiated, 152 patients planned.","Secured global development/commercial rights to levosimendan in PH-HFpEF; new patent issued (US 11,969,424).","Topline data from LEVEL expected second half 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252090,"accession_number":"0001654954-24-003775","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenax Therapeutics reports FY2023 net loss $7.7M; Phase 3 LEVEL trial underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $9.8M at Dec 31, 2023; Feb 2024 public offering netted ~$8.0M.","Net loss $7.7M (FY2023) vs $11.0M (FY2022); R&D expense down to $3.2M.","First patient enrolled in Phase 3 LEVEL study for TNX-103 (oral levosimendan) in PH-HFpEF.","Secured global commercial and IP rights for levosimendan in PH-HFpEF; topline data expected H2 2025.","KOL event 'LEVEL Setting' scheduled for April 18, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252089,"accession_number":"0001654954-24-002134","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2024-02-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tenax Therapeutics regains Nasdaq minimum float compliance; deficiency closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Feb 22, 2024 confirming over 500,000 publicly held shares.","Regained compliance with Nasdaq Listing Rule 5550(a)(4) regarding minimum public float.","Prior deficiency notice on Jan 11, 2024 has been resolved and matter closed.","Company remains listed on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252088,"accession_number":"0001654954-24-001923","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Tenax Therapeutics expands levosimendan license to worldwide rights from Orion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment expands Tenax's exclusive global rights to levosimendan for PH-HFpEF from North America to worldwide.","Royalty rates improved to high single-digit to low-teen percentages; maximum cost of goods reduced.","Milestone payments: $10M on US FDA approval (increased), $5M on Japan approval; up to $45M for commercial milestones.","Tenax retains right of first negotiation for all indications except neurological, which are excluded."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252087,"accession_number":"0001654954-24-001591","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2024-02-12T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Tenax Therapeutics prices $9M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1.6M shares or pre-funded warrants plus 3.2M common warrants at $5.65/unit.","Gross proceeds ~$9M; net proceeds ~$8M after fees and expenses.","Net proceeds to fund Phase 3 LEVEL trial of oral levosimendan in PH-HFpEF.","Roth Capital Partners acted as exclusive placement agent; offering closed Feb 12, 2024.","Post-offering shares outstanding: 1,766,023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252086,"accession_number":"0001654954-24-001465","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Tenax Therapeutics enrolls first patient in Phase 3 LEVEL study for TNX-103 in PH-HFpEF; topline data expected H2 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient enrolled in Phase 3 LEVEL study of oral TNX-103 (levosimendan) for PH-HFpEF; 152-patient trial.","Over 40 U.S. and Canadian sites agreed to participate, including Mayo, Harvard, Northwestern.","Topline data forecast for second half of 2025.","FDA does not require long-term CV outcomes trial, reducing cost and time to registration.","Patent estate protects TNX-103 through at least 2040."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252085,"accession_number":"0001654954-24-001349","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"USPTO allows patent covering levosimendan use in PH-HFpEF through 2040","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["USPTO Notice of Allowance for patent covering oral (TNX-103), IV, subcutaneous levosimendan, active metabolites, and drug combos for PH-HFpEF.","Once granted, patent provides IP protection until Dec 2040, may qualify for patent term extension beyond 2040.","Third patent granted to Tenax since March 2023 protecting levosimendan for PH-HFpEF.","Phase 3 LEVEL study (NCT05983250) ongoing: 152 patients randomized, primary endpoint 6-minute walk distance at Week 12."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252084,"accession_number":"0001654954-24-000770","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tenax Therapeutics regains compliance with Nasdaq minimum bid price rule","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq written confirmation on Jan 18, 2024, after 10 consecutive trading days (Jan 3-17) closing at $1.00 or greater.","Originally notified of bid price deficiency on March 29, 2023; later granted extension through March 25, 2024.","Compliance achieved ahead of extension deadline; delisting risk removed.","Bid Price Rule (Nasdaq Listing Rule 5550(a)(2)) matter now closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252083,"accession_number":"0001654954-24-000523","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2024-01-12T23:59:59+00:00","items":["3.01","5.02","9.01"],"status":"ready","headline":"Tenax Therapeutics receives Nasdaq delisting notice; appoints interim CFO Lawrence Hoffman","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Tenax on Jan 11, 2024 that it fails minimum 500,000 publicly held shares after 1-for-80 reverse split.","Company has until Feb 26, 2024 to submit a compliance plan; no immediate effect on listing or trading.","Lawrence Hoffman appointed Interim CFO effective Jan 11, 2024, succeeding Eliot Lurier (deceased).","Hoffman will be paid $416/hour through Danforth Advisors consulting agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252082,"accession_number":"0001654954-24-000269","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Tenax Therapeutics announces 1-for-80 reverse stock split effective Jan 2, 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reverse split at 1:80 ratio effective 5:00 pm ET on Jan 2, 2024; trading on Nasdaq split-adjusted Jan 3 under TENX.","Pre-split shares: 23,862,434; post-split approximately 298,281 shares outstanding.","No fractional shares issued; odd-lot holders receive one whole share for fractional interests.","Primary purpose: regain compliance with Nasdaq minimum $1.00 bid price requirement (Rule 5550(a)(2)).","Authorized shares unchanged at par value $0.0001; proportional adjustments to options and warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269610,"accession_number":"0001654954-23-015069","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2023-12-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Tenax Therapeutics shareholders approve reverse stock split authorization","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio range 1:10 to 1:80, exact ratio set by board; authorized until Nov 30, 2024.","For: 6,198,812; Against: 5,364,151; Abstain: 23,186; no broker non-votes.","Adjournment proposal also approved (6,308,531 for, 5,052,193 against) but not used."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269609,"accession_number":"0001654954-23-014103","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA clears IND for Tenax's TNX-103 (oral levosimendan) for PH-HFpEF; Phase 3 LEVEL study to start Q4 2023","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for TNX-103 (oral levosimendan) to treat PH-HFpEF, enabling Phase 3 LEVEL study in Q4 2023.","FDA agreed to 6-minute walk distance as primary endpoint; no requirement for cardiovascular outcomes trial.","Patent protection for oral levosimendan in PH-HFpEF until end of 2040; no FDA-approved treatments exist.","More than 2/3 of research sites selected; 90% of prior HELP study sites agreed to participate.","Estimated North American patient population >2 million by 2030; high unmet medical need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286606,"accession_number":"0001654954-23-012433","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2023-09-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Tenax Therapeutics gets Nasdaq extension to March 25, 2024 for $1 bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted extension through March 25, 2024 to regain compliance with $1.00 minimum bid price (Rule 5550(a)(2)).","Original compliance period ended Sept. 25, 2023; extension provides six additional months.","If bid price closes at $1.00+ for ten consecutive days, Nasdaq will confirm compliance.","If not compliant by March 25, 2024, Nasdaq will issue delisting notice; company may appeal.","Company evaluating options including reverse stock split; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286605,"accession_number":"0001654954-23-010854","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2023-08-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Tenax Therapeutics amends bylaws to lower quorum to one-third, allow director removal without cause","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum for stockholder meetings reduced to one-third of shares entitled to vote from previous higher threshold.","Directors may now be removed with or without cause by majority vote of stockholders.","Amended bylaws add provisions clarifying mechanics for adjourning stockholder meetings.","Other ministerial, clarifying and conforming changes were included in the Fourth Amended and Restated Bylaws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286604,"accession_number":"0001654954-23-009414","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2023-07-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Tenax Therapeutics receives U.S. patent for oral levosimendan (TNX-103) in PH-HFpEF, expiring 2040","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["USPTO granted Patent No. 11,701,355 for oral levosimendan (TNX-103) to treat PH-HFpEF, with exclusivity through December 2040.","No FDA-approved treatments exist for PH-HFpEF, which affects over 1.6 million North Americans, projected to exceed 2 million by 2030.","Phase 2 HELP study showed statistically significant improvement in 6-minute walk distance for levosimendan.","Tenax intends to initiate a Phase 3 trial of TNX-103 in 2023, planning to demonstrate efficacy in this underserved patient population.","Patent builds on existing IP for IV and subcutaneous levosimendan formulations for PH-HFpEF."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306522,"accession_number":"0001654954-23-007952","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2023-06-13T23:59:59+00:00","items":[],"status":"ready","headline":"Tenax shareholders reject reverse stock split and stock plan amendment; directors elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected: June Almenoff, Michael Davidson, Declan Doogan, Christopher Giordano, Robyn Hunter, Gerald Proehl, Stuart Rich.","Reverse stock split proposal failed: 5,560,628 for, 5,268,941 against, 112,897 abstain.","Stock incentive plan amendment (increase by 2.75M shares) failed: 2,775,491 for, 4,415,521 against, 262,926 abstain, 3,488,528 broker non-votes.","Ratification of Cherry Bekaert as auditor approved: 9,331,120 for, 1,014,740 against, 596,606 abstain.","Adjournment proposal approved (7,279,249 for) but not used; meeting concluded without adjournment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306521,"accession_number":"0001654954-23-007426","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2023-05-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Tenax Therapeutics receives USPTO Notice of Allowance for oral levosimendan patent in PH-HFpEF","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Patent covers oral levosimendan (TNX-103) for PH-HFpEF; term through Dec 2040, possible extension beyond.","No FDA-approved treatments exist for PH-HFpEF, affecting >1.6M North Americans, projected >2M by 2030.","Phase 2 HELP study showed levosimendan improved 6-minute walk by 29 meters (p=0.03) vs placebo.","Tenax intends to initiate Phase 3 trial of oral formulation in 2023; FDA agreed 6-minute walk test as primary endpoint."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306520,"accession_number":"0001654954-23-004663","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2023-04-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Tenax prioritizes oral levosimendan Phase 3 for PH-HFpEF in 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company to initiate Phase 3 trial of TNX-103 (oral levosimendan) for PH-HFpEF in 2023.","PH-HFpEF affects >1.6M North Americans; no FDA-approved therapy exists.","Patent estate expanded; protection through at least 2040 with additional IP expected in 2023.","FDA agreed Phase 3 endpoints: 6-minute walk distance at 12 weeks or clinical worsening at 24 weeks.","Imatinib Phase 3 deferred beyond 2023 pending fundraising and strategic review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325653,"accession_number":"0001654954-23-003859","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Tenax Therapeutics receives Nasdaq bid price deficiency notice; 180 days to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Tenax on March 29, 2023 that bid price closed below $1.00 for 30 consecutive business days.","Company has until September 25, 2023 to regain compliance by closing at $1.00+ for 10 consecutive days.","If not cured, Company may be eligible for additional 180-day period if it meets other listing standards.","No immediate effect on listing; stock continues trading under TENX on Nasdaq Capital Market.","Company evaluating options including potential reverse stock split to cure deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325652,"accession_number":"0001654954-23-003357","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2023-03-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Tenax Therapeutics receives US patent for IV levosimendan in PH-HFpEF, expiring Dec 2040","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["U.S. Patent No. 11,607,412 covers IV levosimendan for pulmonary hypertension with HFpEF.","Patent protection extends until December 2040, strengthening IP for levosimendan.","No FDA-approved treatments exist for PH-HFpEF, which affects >1.6M North Americans.","Levosimendan combines K+ATP channel activation and Ca++ sensitization, distinct MoA.","HELP Study showed 29-meter improvement in 6-minute walk distance vs placebo (p=0.03)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325651,"accession_number":"0001654954-23-001580","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2023-02-10T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"Tenax Therapeutics terminates HQ lease with $169,867 payment; no further obligations","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease termination with CCP Concourse, LLC, effective Feb 8, 2023.","Company paid $169,867.41 to Landlord to settle all claims and obligations.","Lease originally expired June 30, 2024; company vacated premises Oct 31, 2022.","No remaining rent or future obligations under the Lease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325650,"accession_number":"0001654954-23-001434","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2023-02-07T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Tenax Therapeutics raises ~$15.6M in public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 8,666,666 shares (or pre-funded warrants) plus 17,333,332 warrants at $1.80/unit.","Gross proceeds ~$15.6M; net proceeds ~$14.1M after fees and expenses.","Warrants exercisable at $2.25/share, expire 5 years from issuance.","Proceeds to fund Phase 3 trial of imatinib for PAH and levosimendan for PH-HFpEF.","Offering closed Feb 7, 2023; post-closing shares outstanding 9,265,099."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325649,"accession_number":"0001654954-23-001174","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2023-02-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Tenax Therapeutics granted US patent covering IV levosimendan for PH-HFpEF until 2040","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["USPTO Notice of Allowance for patent covering IV levosimendan in PH-HFpEF; patent expected to last until 2040.","No FDA-approved treatments exist for PH-HFpEF, which affects over 1.5 million patients in the US.","HELP Study showed levosimendan improved 6-minute walk distance by 29 meters (p=0.03); FDA accepted endpoint for Phase 3.","Patent builds on existing U.S. Patent No. 11,213,524 for subcutaneous levosimendan issued Jan 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325648,"accession_number":"0001654954-23-000627","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2023-01-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tenax regains compliance with Nasdaq minimum bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq confirmed compliance on Jan 20, 2023 after stock closed at $1.00+ for ten consecutive trading days.","Previously notified of deficiency on Feb 17, 2022; extension granted through Feb 13, 2023.","Matter is now closed; no further action required to maintain listing under Bid Price Rule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325647,"accession_number":"0001654954-23-000110","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2023-01-04T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Tenax Therapeutics effects 1-for-20 reverse stock split to meet Nasdaq minimum bid price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-20 ratio effective 5:00 p.m. ET on January 4, 2023.","Shares outstanding reduced from 45,836,215 to approximately 2,291,811; no fractional shares issued, rounded up.","Stock to trade split-adjusted on Nasdaq under symbol TENX starting January 5, 2023; new CUSIP 88032L506.","Reverse split was approved by shareholders on June 9, 2022; board set ratio on December 15, 2022.","Purpose is to regain compliance with Nasdaq's minimum $1.00 bid price requirement for continued listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343398,"accession_number":"0001654954-22-013566","cik":34956,"company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","form_type":"8-K","filed_at":"2022-10-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Tenax Therapeutics announces positive oral levosimendan data in PH-HFpEF patients at HFSA meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["18 PH-HFpEF patients transitioned from IV to oral levosimendan with no serious adverse events reported.","6-minute walk distance improved by mean 13.1 m; BNP decreased by mean 133.3 pg/dL; NT-proBNP decreased by 239.4 pg/dL.","KCCQ overall summary score improved 3.7 points; physical and clinical summary scores also improved.","Oral formulation at 3-4 mg/day deemed safe and effective for chronic use, supporting Phase 3 testing.","Data presented at HFSA Scientific Sessions 2022; investigators concluded oral levosimendan is well tolerated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":312731614.7651515,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-10-11T23:59:59+00:00|343398"}